Cargando…

Elevated Serum Levels of Soluble ST2 Are Associated With Plaque Vulnerability in Patients With Non-ST-Elevation Acute Coronary Syndrome

Background: Recent studies have suggested that soluble suppression of tumorigenicity-2 (sST2), an inflammation-related protein receptor, is associated with atherosclerotic diseases. This study aimed to investigate the potential predictive value of sST2 on plaque vulnerability by assessing whether el...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Guqing, Qian, Yuxuan, Sheng, Xincheng, Sun, Jiateng, Wu, Zhinan, Liao, Fei, Feng, Qi, Yin, Yan, Ding, Song, Pu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341076/
https://www.ncbi.nlm.nih.gov/pubmed/34368249
http://dx.doi.org/10.3389/fcvm.2021.688522
_version_ 1783733868876005376
author Luo, Guqing
Qian, Yuxuan
Sheng, Xincheng
Sun, Jiateng
Wu, Zhinan
Liao, Fei
Feng, Qi
Yin, Yan
Ding, Song
Pu, Jun
author_facet Luo, Guqing
Qian, Yuxuan
Sheng, Xincheng
Sun, Jiateng
Wu, Zhinan
Liao, Fei
Feng, Qi
Yin, Yan
Ding, Song
Pu, Jun
author_sort Luo, Guqing
collection PubMed
description Background: Recent studies have suggested that soluble suppression of tumorigenicity-2 (sST2), an inflammation-related protein receptor, is associated with atherosclerotic diseases. This study aimed to investigate the potential predictive value of sST2 on plaque vulnerability by assessing whether elevated serum levels of sST2 are associated with vulnerable plaque features in patients with non-ST-elevation acute coronary syndrome (ACS). Methods: A total of 120 patients with non-ST-elevation ACS (167 lesions) were prospectively enrolled and evaluated by standard coronary computed tomography angiography (CCTA) and coronary angiography in this study. Serum sST2 levels were measured by ELISA (Presage(®) ST2 Assay Kit, Critical Diagnostics), and semiautomated software (QAngioCT, Medis) was used to quantify coronary plaques. Results: The included patients were divided into 4 groups by serum sST2 level quartiles. Volumetric analysis of the whole lesion revealed that patients with higher sST2 levels had a larger absolute necrotic core (NC) volume (Quartile 4 vs. Quartile 1, 86.16 ± 59.71 vs. 45.10 ± 45.80 mm(3), P = 0.001; Quartile 4 vs. Quartile 2, 86.16 ± 59.71 vs. 50.22 ± 42.56 mm(3), P = 0.002) and a higher NC percentage (Quartile 4 vs. Quartile 1, 35.16 ± 9.82 vs. 23.21 ± 16.18%, P < 0.001; Quartile 4 vs. Quartile 2, 35.16 ± 9.82% vs. 22.50 ± 14.03%, P < 0.001; Quartile 4 vs. Quartile 3, 35.16 ± 9.82% vs. 25.04 ± 14.48%, P < 0.001). Correlation analysis revealed that serum sST2 levels were positively correlated with the NC (r = 0.323, P < 0.001) but negatively correlated with dense calcium (r = −0.208, P = 0.007). Furthermore, among those with plaque calcification, patients with spotty calcification exhibited higher serum sST2 levels than those with large calcification (26.06 ± 16.54 vs. 17.55 ± 7.65 ng/mL, P = 0.002). No significant differences in plaque components at the level of the minimal lumen area (MLA) were found among the groups. Conclusions: Serum sST2 levels were correlated with different coronary plaque components in patients with non-ST-elevation ACS. A higher serum level of sST2 was correlated with plaque vulnerability. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT04797819.
format Online
Article
Text
id pubmed-8341076
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83410762021-08-06 Elevated Serum Levels of Soluble ST2 Are Associated With Plaque Vulnerability in Patients With Non-ST-Elevation Acute Coronary Syndrome Luo, Guqing Qian, Yuxuan Sheng, Xincheng Sun, Jiateng Wu, Zhinan Liao, Fei Feng, Qi Yin, Yan Ding, Song Pu, Jun Front Cardiovasc Med Cardiovascular Medicine Background: Recent studies have suggested that soluble suppression of tumorigenicity-2 (sST2), an inflammation-related protein receptor, is associated with atherosclerotic diseases. This study aimed to investigate the potential predictive value of sST2 on plaque vulnerability by assessing whether elevated serum levels of sST2 are associated with vulnerable plaque features in patients with non-ST-elevation acute coronary syndrome (ACS). Methods: A total of 120 patients with non-ST-elevation ACS (167 lesions) were prospectively enrolled and evaluated by standard coronary computed tomography angiography (CCTA) and coronary angiography in this study. Serum sST2 levels were measured by ELISA (Presage(®) ST2 Assay Kit, Critical Diagnostics), and semiautomated software (QAngioCT, Medis) was used to quantify coronary plaques. Results: The included patients were divided into 4 groups by serum sST2 level quartiles. Volumetric analysis of the whole lesion revealed that patients with higher sST2 levels had a larger absolute necrotic core (NC) volume (Quartile 4 vs. Quartile 1, 86.16 ± 59.71 vs. 45.10 ± 45.80 mm(3), P = 0.001; Quartile 4 vs. Quartile 2, 86.16 ± 59.71 vs. 50.22 ± 42.56 mm(3), P = 0.002) and a higher NC percentage (Quartile 4 vs. Quartile 1, 35.16 ± 9.82 vs. 23.21 ± 16.18%, P < 0.001; Quartile 4 vs. Quartile 2, 35.16 ± 9.82% vs. 22.50 ± 14.03%, P < 0.001; Quartile 4 vs. Quartile 3, 35.16 ± 9.82% vs. 25.04 ± 14.48%, P < 0.001). Correlation analysis revealed that serum sST2 levels were positively correlated with the NC (r = 0.323, P < 0.001) but negatively correlated with dense calcium (r = −0.208, P = 0.007). Furthermore, among those with plaque calcification, patients with spotty calcification exhibited higher serum sST2 levels than those with large calcification (26.06 ± 16.54 vs. 17.55 ± 7.65 ng/mL, P = 0.002). No significant differences in plaque components at the level of the minimal lumen area (MLA) were found among the groups. Conclusions: Serum sST2 levels were correlated with different coronary plaque components in patients with non-ST-elevation ACS. A higher serum level of sST2 was correlated with plaque vulnerability. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT04797819. Frontiers Media S.A. 2021-07-22 /pmc/articles/PMC8341076/ /pubmed/34368249 http://dx.doi.org/10.3389/fcvm.2021.688522 Text en Copyright © 2021 Luo, Qian, Sheng, Sun, Wu, Liao, Feng, Yin, Ding and Pu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Luo, Guqing
Qian, Yuxuan
Sheng, Xincheng
Sun, Jiateng
Wu, Zhinan
Liao, Fei
Feng, Qi
Yin, Yan
Ding, Song
Pu, Jun
Elevated Serum Levels of Soluble ST2 Are Associated With Plaque Vulnerability in Patients With Non-ST-Elevation Acute Coronary Syndrome
title Elevated Serum Levels of Soluble ST2 Are Associated With Plaque Vulnerability in Patients With Non-ST-Elevation Acute Coronary Syndrome
title_full Elevated Serum Levels of Soluble ST2 Are Associated With Plaque Vulnerability in Patients With Non-ST-Elevation Acute Coronary Syndrome
title_fullStr Elevated Serum Levels of Soluble ST2 Are Associated With Plaque Vulnerability in Patients With Non-ST-Elevation Acute Coronary Syndrome
title_full_unstemmed Elevated Serum Levels of Soluble ST2 Are Associated With Plaque Vulnerability in Patients With Non-ST-Elevation Acute Coronary Syndrome
title_short Elevated Serum Levels of Soluble ST2 Are Associated With Plaque Vulnerability in Patients With Non-ST-Elevation Acute Coronary Syndrome
title_sort elevated serum levels of soluble st2 are associated with plaque vulnerability in patients with non-st-elevation acute coronary syndrome
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341076/
https://www.ncbi.nlm.nih.gov/pubmed/34368249
http://dx.doi.org/10.3389/fcvm.2021.688522
work_keys_str_mv AT luoguqing elevatedserumlevelsofsolublest2areassociatedwithplaquevulnerabilityinpatientswithnonstelevationacutecoronarysyndrome
AT qianyuxuan elevatedserumlevelsofsolublest2areassociatedwithplaquevulnerabilityinpatientswithnonstelevationacutecoronarysyndrome
AT shengxincheng elevatedserumlevelsofsolublest2areassociatedwithplaquevulnerabilityinpatientswithnonstelevationacutecoronarysyndrome
AT sunjiateng elevatedserumlevelsofsolublest2areassociatedwithplaquevulnerabilityinpatientswithnonstelevationacutecoronarysyndrome
AT wuzhinan elevatedserumlevelsofsolublest2areassociatedwithplaquevulnerabilityinpatientswithnonstelevationacutecoronarysyndrome
AT liaofei elevatedserumlevelsofsolublest2areassociatedwithplaquevulnerabilityinpatientswithnonstelevationacutecoronarysyndrome
AT fengqi elevatedserumlevelsofsolublest2areassociatedwithplaquevulnerabilityinpatientswithnonstelevationacutecoronarysyndrome
AT yinyan elevatedserumlevelsofsolublest2areassociatedwithplaquevulnerabilityinpatientswithnonstelevationacutecoronarysyndrome
AT dingsong elevatedserumlevelsofsolublest2areassociatedwithplaquevulnerabilityinpatientswithnonstelevationacutecoronarysyndrome
AT pujun elevatedserumlevelsofsolublest2areassociatedwithplaquevulnerabilityinpatientswithnonstelevationacutecoronarysyndrome